Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Maintains $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has reiterated a Neutral rating for Collegium Pharmaceutical (NASDAQ:COLL) and maintained a price target of $37.
October 11, 2024 | 5:58 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler has reiterated a Neutral rating for Collegium Pharmaceutical, maintaining a $37 price target. This suggests that the analyst does not expect significant short-term price movement.
The reiteration of a Neutral rating and maintenance of the price target at $37 indicates that the analyst does not foresee significant changes in the stock's valuation in the short term. This suggests stability in the stock's price, aligning with the analyst's expectations.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100